Comparative Pharmacology
Head-to-head clinical analysis: FLOWTUSS versus MUCINEX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOWTUSS versus MUCINEX D.
FLOWTUSS vs MUCINEX D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
Mucinex D contains guaifenesin, which is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity and enhance mucus clearance, and pseudoephedrine, a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
Mucinex D contains guaifenesin 600 mg and pseudoephedrine 60 mg per extended-release tablet. Usual adult dose: 1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (CrCl 30–50 mL/min).
Guaifenesin: 1 hour (short t½, requires frequent dosing). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine)
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
Guaifenesin: Renal (primarily as metabolites, <5% unchanged). Pseudoephedrine: Renal (70-90% unchanged, dependent on urine pH)
Category C
Category C
Expectorant
Expectorant/Decongestant Combination